New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome
WHY IT MATTERS
Adults with FCS in the EU now have access to a new treatment option that specifically targets triglyceride reduction, potentially reducing their risk of severe pancreatitis and other complications from extremely high blood fat levels.
The European Medicines Agency has approved a new medicine called Redemplo (plozasiran) for adults with familial chylomicronaemia syndrome (FCS), a rare genetic condition where the body cannot properly break down certain fats in the blood. This medicine helps reduce triglycerides, which are a type of fat that builds up to dangerous levels in people with FCS. The approval means the medicine is now available for patients in the European Union.
Source: European Medicines Agency (EMA) Description: EMA has recommended granting a marketing authorisation in the European Union (EU) for Redemplo (plozasiran) to treat adults with familial chylomicronaemia syndrome (FCS).FCS is… Published: 2026-04-24T07:34:07.000Z Note: EMA announcements cover medicines approved in the EU. Orphan designations may not yet be available in the US.
YOU CAN ACT ON THIS
If you have FCS and live in the EU, ask your doctor whether Redemplo might be appropriate for you and how to access it through your healthcare system.